Future studies should assess the impact of repeat dosing of ASIT in people with ACPA+ RA or who are at risk, to test that hypothesis that ASIT expands and differentiates PD-1+ autoreactive Tregs that control proinflammatory T cells and autoreactive B cells to suppress disease. Here, PDCD1 is linked to rheumatoid arthritis.